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Connective tissue growth factor (CTGF; CCN2) plays a role in the development of diabetic nephropathy (DN). Urinary CTGF
(uCTGF) is elevated in DN patients and has been proposed as a biomarker for disease progression, but it is unknown which
pathophysiological factors contribute to elevated uCTGF. We studied renal handling of CTGF by infusion of recombinant CTGF
in diabetic mice. In addition, uCTGF was measured in type 1 DN patients and compared with glomerular and tubular dysfunction
and damagemarkers. In diabetic mice, uCTGFwas increased and fractional excretion (FE) of recombinant CTGFwas substantially
elevated indicating reduced tubular reabsorption. FE of recombinant CTGF correlated with excretion of endogenous CTGF. CTGF
mRNA was mainly localized in glomeruli and medullary tubules. Comparison of FE of endogenous and recombinant CTGF
indicated that 60% of uCTGF had a direct renal source, while 40% originated from plasma CTGF. In DN patients, uCTGF was
independently associated with markers of proximal and distal tubular dysfunction and damage. In conclusion, uCTGF in DN is
elevated as a result of both increased local production and reduced reabsorption due to tubular dysfunction.We submit that uCTGF
is a biomarker reflecting both glomerular and tubulointerstitial hallmarks of diabetic kidney disease.
1. Introduction
Diabetic nephropathy (DN) is the leading cause of chronic
kidney disease and the primary diagnosis in more than
40% of new patients on dialysis in several parts of the
world including the United States [1]. Identifying the factors
that contribute to the pathogenesis of DN is a critical step
towards halting its progression. Connective tissue growth
factor (CTGF; CCN2) is a matricellular protein involved in
modulation of the extracellular environment and plays a role
in the development and progression of diabetic complications
[2–11]. In DN, increased renal CTGF expression has been
described both in glomeruli and in the tubulointerstitium [4].
UrinaryCTGF (uCTGF) is elevated inDNand correlateswith
markers of disease severity such as urinary albumin excretion
and glomerular filtration rate (GFR) [12–14]. Furthermore,
Hindawi Publishing Corporation
Journal of Diabetes Research
Volume 2015, Article ID 539787, 11 pages
http://dx.doi.org/10.1155/2015/539787
2 Journal of Diabetes Research
uCTGF has been shown to correlate with progression of
microalbuminuria in diabetic patients [15]. Thus urinary
CTGF might be suitable as a biomarker in monitoring DN.
However, to interpret elevated uCTGF in diabetes, it is crucial
to understand the mechanisms behind this elevation.
Both increased intrarenal production and elevated
plasma CTGF have been suggested to account for elevated
uCTGF in DN [13, 14]. We have shown in healthy volunteers
and normoglycemic mice that blockade of proximal tubular
reabsorption results in a major increase in uCTGF [16]. The
aim of this study is to evaluate which factors contribute to
elevated uCTGF in diabetes. In diabetic mice, we measured
the fractional excretion (FE) of both endogenous CTGF and
recombinant CTGF (i.e., not intrarenally derived CTGF) and
examined the renal expression pattern of CTGF. Moreover,
we examined the association between uCTGF and urinary
markers in type 1 diabetic patients.
2. Materials and Methods
2.1. Animal Experiment. Diabetes was induced in nineteen
10–12-week-old male C57BL/6 mice (Harlan, Horst, Nether-
lands) by a single intraperitoneal injection of 200mg/kg
streptozotocin (STZ, Sigma, St. Louis, MO, USA) in sodium
citrate buffer (100mmol/L, pH 4.5). Blood glucose was
determined one week after injection of STZ (MediSense
Precision Xtra, Abbott, Abbott Park, IL, USA). Slow-release
insulin pellets were implanted subcutaneously to stabilize
the condition of the diabetic animals (LinBit, LinShin, Scar-
borough, ON, Canada). Eight control animals were injected
with sodium citrate buffer. Ten weeks after STZ, renal
function parameters and fractional excretion of CTGF were
determined. Twominiosmotic pumps (model 1003D,ALZET,
Cupertino, CA, USA, 100 𝜇L reservoir volume, release rate
of 1 𝜇L/h) were implanted intraperitoneally under isoflurane
anaesthesia. One pump was used for infusion of FITC-
inulin.The other pumpwas used for simultaneous infusion of
recombinant human CTGF (rCTGF, 38 pmol/h) in fourteen
of the diabetic mice and four of the control mice.We used the
proteolytic aminoterminal fragment of CTGF since this is the
predominant form of CTGF detected in plasma and urine [13,
17–19]. To exclude that rCTGF had an effect on endogenous
CTGF mRNA expression in the kidney, we infused four
control mice and five diabetic mice with vehicle. The mice
injected with rCTGF were used to determine FE of rCTGF
and intrarenally derived uCTGF (see below).
Forty-eight hours after pump implantation, mice were
put in metabolic cages overnight for timed urine collection.
Plasma was collected before and after the urine collection,
CTGF levels were determined, and time-weighted averages
of plasma CTGF were calculated. All samples and metabolic
cages were protected from light. Mice were killed 3 days after
pump implantation and organs were harvested. All experi-
ments were approved by the Animal Ethical Committee of
the University of Utrecht and performed in accordance with
national guidelines for the care and handling of animals.
2.2. Diabetic Patient Study. Three hundred and forty-nine
well-characterized adult type 1 diabetic patients were selected
from the outpatient clinic at Steno Diabetes Center (Copen-
hagen, Denmark). Forty-three of the patients with diabetic
nephropathy had been previously analysed in a longitudinal
study examining the impact of Losartan on uCTGF [12]. The
studywas approved by the Ethical Committee of Copenhagen
County and performed in accordance with the Declaration
of Helsinki. Demographic and clinical data were recorded,
including age, sex, duration of diabetes, and body mass
index. Creatinine was determined in venous blood samples
using the Cobas Mira Plus (Roche, Basel, Switzerland).
HbA1c was determined using variant high-performance liq-
uid chromatograph (Bio-Rad Laboratories, Hercules, CA,
USA). The estimated GFR (eGFR) was calculated using
the Modification of Diet in Renal Disease study method
[20]. Albumin excretion rate (AER) was determined in
24 h urine collections using turbidimetry. Macroalbuminuria
was defined as albuminuria>300mg/24 h,microalbuminuria
as albuminuria 30–300mg/24 h, and normoalbuminuria as
albuminuria <30mg/24 h. Sixty patients were excluded from
analysis because of incomplete data due to insufficient sample
availability or incomplete patient characteristics.
2.3. CTGF Proteins, Antibodies, and ELISA. Recombinant
human CTGFs and anti-CTGF antibodies were supplied
by FibroGen Inc. (San Francisco, CA, USA). CTGF levels
in plasma and urine were determined by sandwich ELISA,
using specific antibodies (FibroGen) directed against distinct
epitopes in the aminoterminal fragment of CTGF, detecting
both full length CTGF and the N-fragment (N-CTGF), as
described previously [16]. Two ELISA assays were used: an
assay for detection of human or rCTGF in either human
or mouse samples and an assay for detection of rodent
CTGF in mouse samples. The antibody used for detection
in the human CTGF assay does not cross-react with rodent
CTGF and allows specific determination of rCTGF in mouse
samples.
2.4. Laboratory Measurements (Patient Studies). CTGF was
determined as described above. Urinary 𝛼1-microglobulin
(𝛼1M) was measured by competition enzyme immunoassay.
Maxisorp microtiter plates (Nunc, Rochester, NY, USA) were
coated with 0.4𝜇g antigen (Fitzgerald Industries Interna-
tional, Acton, MA, USA). After washing, 20-time diluted
samples were incubated with biotinylated detection anti-
body (chicken anti-human 𝛼1-microglobulin; ICL, Newberg,
OR, USA). After washing, wells were incubated with HRP-
conjugated streptavidin and binding was detected bymeasur-
ing HRP activity using o-phenylenediamine as chromogenic
substrate. Urinary 𝛽2-microglobulin (𝛽2M) (Anogen, Mis-
sissauga, ON, Canada), heart-type fatty acid-binding pro-
tein (H-FABP) (Hytest, Turku, Finland), immunoglobu-
lin G subclass 4 (IgG4), kidney injury molecule-1 (KIM-
1), and neutrophil gelatinase-associated lipocalin (NGAL)
(R&D Systems, Minneapolis, MN, USA) were measured by
ELISA, as described previously [21]. Urinary N-acetyl-𝛽-
glucosaminidase (NAG) was measured using a modified
enzyme assay according to Lockwood and Bosmann and cor-
rected for nonspecific conversion (HaemoScan, Groningen,
Netherlands) [22].
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2.5. Preparation of FITC-Inulin Solution and Fluorescence
Measurement. Prior to the animal experiments, 5% FITC-
inulin (Sigma-Aldrich, Zwijndrecht, Netherlands) was dis-
solved in 0.9% NaCl by heating in boiling water and dialyzed
to remove residual free FITC. The dialyzed FITC-inulin
solution was sterilized by filtration through a 0.20𝜇m syringe
filter (Corning, New York, NY, USA).
Fluorescence of plasma and urine was measured within
hours after collection in black 96-well plates (Fluotrac,
Greiner Bio-One, Kremsmu¨nster, Austria) in a FLUOstar
Optima (BMG Labtech, Offenburg, Germany) at 485 nm
excitation and 538 nm emission. Plasma and urine samples
were buffered to pH 7.4 by dilution with HEPES 50mmol/L
pH 7.4 (5- and 10-fold, resp.) before fluorescence measure-
ment. Matrix correction was applied for the standard curves.
2.6. Histology. For routine histological examination and
scoring of tubular atrophy (TA), formalin-fixed, paraffin-
embedded (FFPE) tissue sections were stained with periodic
acid-Schiff (PAS). TA was defined as the presence of tubules
with thickened tubular basementmembranes and/or atrophic
cells lining the tubules, with loss of brush border. TA was
scored by two skilled observers in ten randomly selected
cortical areas on ×100 magnification. The following semi-
quantitative scale was used: 0: no TA; 1: >0–10% TA (>0–10%
of tubuli in the field shows atrophy); 2: 10–25% TA; 3: 25–
50% TA; 4: 50–75% TA; 5: 75–100% TA. The average of ten
fields was used for further statistical analysis. Photographs
were taken on aNikon Eclipse E800microscope with aNikon
DXM1200 digital camera using the Nikon ACT-1 software
version 2.70 (Nikon Netherlands, Lijnden, Netherlands).
2.7. In Situ Hybridization. Localization of CTGF mRNA
was investigated as described in detail previously [23].
Briefly, 6 𝜇m thick FFPE tissue sections were dewaxed and
rehydrated, incubated with proteinase K, postfixed, prehy-
bridized, and hybridized with a 542-nt antisense CTGF DIG-
labeled riboprobe for 16 h at 70∘C.Uponwashing, boundDIG
was detected using alkaline phosphatase-conjugated sheep
anti-DIG and NBT/BCIP (Roche, Almere, Netherlands).
Incubation with sense DIG-labeled riboprobe was applied as
negative control.
2.8. Quantitative Reverse Transcription PCR. For isolation
of cortical mRNA, about 30mg of the renal pole was
cut using a scalpel. For medullary mRNA, fifteen 10 𝜇m
cryosections per sample were put on a glass slide and
medulla was identified based on location and morphology
and microdissected using a scalpel. The remaining tissue was
stained with hematoxylin and eosin to check the accuracy
of medullary microdissection. Total RNA was isolated using
the RNeasy RNA isolation kit (QIAGEN Benelux, Venlo,
Netherlands). RNAwas reverse-transcribed with SuperScript
II Reverse Transcriptase (Invitrogen, Paisley, UK). Quantita-
tive reverse transcription PCR (qRT-PCR) was performed on
an Applied Biosystems 7900HT Fast Real-Time PCR System
(Applied Biosystems, Nieuwerkerk aan den IJssel, Nether-
lands). Expression levels of Ctgf and the internal references,
Tbp and Gapdh, were determined using Applied Biosystems
inventoried Taqman Gene Expression Assays, containing
primers and probe. Gene expression was quantified using the
2
−ΔΔCt method [24].
2.9. Calculations and Statistical Analysis. Data are presented
asmean± SDormedian (interquartile range). UrinaryCTGF,
fractional CTGF excretion, CTGF mRNA (fold change),
urinary markers, and human plasma CTGF data were
logarithmically transformed to allow parametric analysis.
Undetectable concentrations were set at half of the lowest
detectable level. Urinary IgG4 was dichotomized as greater
than or less than the detection limit because of a high
proportion of subjects with undetectable levels. Differences
were calculated using Student’s t-test or Mann-Whitney 𝑈
test where appropriate. Correlations between variables were
evaluated by Pearson’s and Spearman’s correlation coefficients
(𝑟 and 𝜌, resp.) where appropriate. Multiple linear regression
analysis was performed to identify parameters independently
associated with uCTGF. To explore the association between
clusters of biomarkers and uCTGF, we used mean standard
deviation scores (𝑍-scores), a method previously described
by Schram et al. [25]. For each individual, the values of each
marker were expressed as a 𝑍-score, that is, (value in the
individual minus the mean value in the study population)
divided by the standard deviation. The proximal tubular
reabsorption (PTR) 𝑍-score was then calculated as (𝑍-score
of 𝛼1M + 𝑍-score of 𝛽2M)/2, the proximal tubular injury
(PTI) 𝑍-score as (𝑍-score of KIM-1 + 𝑍-score of NAG + 𝑍-
score of NGAL)/3, and the combined proximal tubule (PT)
𝑍-score as (PTR 𝑍-score + PTI 𝑍-score)/2. This approach
was used in order to avoid underestimating the associations
between the different markers and uCTGF. For all compar-
isons, a𝑃 value< 0.05 (two-tailed)was considered significant.
The statistical analysis was performed using PASW Statistics
software version 18.03 for Macintosh (SPSS Inc., Chicago,
IL, USA) and GraphPad Prism software version 4.03 for
Windows (GraphPad Software, San Diego, CA, USA).
In the diabetic mice study, urinary CTGF was expressed
as 24-hour excretion rates. Urinary CTGF expressed per
g creatinine provided similar results (see supplementary
figures in the Supplementary Material available online at
http://dx.doi.org/10.1155/2015/539787). Fractional excretion
(FE) of CTGF was calculated as follows:
FECTGF =
[CTGF]urine × [inulin]plasma
[CTGF]plasma × [inulin]urine
× 100%. (1)
Assuming that rCTGF and endogenous CTGF (eCTGF) are
handled similarly by the kidney and taking into account that
rCTGF can only appear in urine by filtration from plasma
whereby FErCTGF is only determined by CTGF filtered from
the plasma (and not by intrarenal CTGF production), the
relative contribution of plasma-derived eCTGF to urinary
eCTGF could be estimated as follows:
Fraction of ueCTGF derived from plasma
=
FErCTGF
FEeCTGF
.
(2)
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Table 1: Characteristics of control mice and diabetic mice (parameters at termination of the study).
Control Diabetes
𝑁 8 19
Plasma glucose (mmol/L) 11.6 (9.8–13.1) 21.5 (18.1–27.8)a
Body weight at start (g) 25.5 (24.7–26.9) 26.0 (24.9–27.0)
Body weight at termination (g) 25.6 (24.7–27.9) 22.1 (21.1–23.2)a
Kidney weight (mg) 150 (141–160) 139 (128–148)a
Kidney weight/body weight (mg/g) 5.7 (5.4–5.9) 6.3 (5.9–6.7)a
GFR (mL kg−1min−1; inulin) 10.5 (8.4–12.4) 7.7 (6.3–9.4)a
AER (𝜇g/24 h) 135 (77–158) 400 (242–544)a
Plasma CTGF (pmol/l) 230 (185–295) 340 (290–370)a
Urinary CTGF (fmol/24 h) ≤57 999 (190–2946)a
Data are median (interquartile range); a𝑃 < 0.05 versus control mice in Mann-Whitney 𝑈 test.
The relative contribution of intrarenally derived CTGF to
urinary eCTGF could be estimated as follows:
Fraction of ueCTGF derived from a local intrarenal source
= 1−
FErCTGF
FEeCTGF
.
(3)
One diabetic mouse was excluded from this calculation
because of unreliable measurements (below lower limit of
quantification).
The absolute amount of urinary eCTGF derived from an
intrarenal source was estimated as follows:
Excretion of intrarenally-derived eCTGF
= excretion of eCTGF×(1−
FErCTGF
FEeCTGF
) .
(4)
Renal clearance of FITC-inulin was calculated by the stan-
dard formula.
3. Results
3.1. Reduced Tubular Reabsorption Is a Major Determinant
of Increased Urinary CTGF in Diabetic Mice. Diabetes was
induced in C57BL/6 mice with STZ which caused pro-
nounced hyperglycemia within one week. At the end of the
study period the diabetic mice had developed DN, for exam-
ple, increased albuminuria and decreased GFR (Table 1).
Urinary excretion of CTGF was markedly elevated in all
diabetic mice (999 fmol/24 h (190–2946), 𝑃 < 0.0001) while
in control mice uCTGF was measurable in only a minority,
with a maximum of 57 fmol/24 h. Plasma CTGF was mildly
increased in diabetic mice (340 pmol/L (290–370) versus
230 pmol/L (185–295) in control mice, 𝑃 = 0.003).
To establish the influence of diabetic kidney disease
on the renal handling of CTGF, we infused recombinant
human CTGF (rCTGF) and FITC-inulin simultaneously by
miniosmotic pumps. For detection of rCTGF levels we used
an ELISA that does not cross-react with endogenous CTGF
(eCTGF). This allowed us to study urinary excretion of
plasma derived CTGF independent from intrarenally pro-
duced CTGF, since urinary recombinant CTGF is exclusively
derived fromfiltered plasma rCTGF.On the contrary, urinary
endogenous CTGF (ueCTGF) might also be derived from
intrarenal production. Since CTGF is almost completely
filtered from the plasma (sieving coefficient 0.74) [16] and
rCTGF clearance and FITC-inulin clearance were not differ-
entially affected between control and diabeticmice (𝑃 = 0.53,
data not shown), fractional excretion of rCTGF (FErCTGF)
could be regarded as ameasure of tubular CTGF passage with
increased FErCTGF reflecting reduced tubular reabsorption
of CTGF. We observed that in diabetic mice FErCTGF was
strongly increased (72-fold, 𝑃 = 0.004, Figure 1(a)), while
in control mice tubular reabsorption of (filtered) rCTGF was
virtually complete. FErCTGF showed a tight linear correlation
with urinary excretion of endogenous CTGF (ueCTGF)
in diabetic mice (𝑟 = 0.95, 𝑃 < 0.0001, slope 1.1
on a logarithmic scale (Figure 1(b))) and emerged as an
independent determinant of ueCTGF (𝛽 = 1.3, 𝑃 <
0.001) in a multivariate model that included the following
parameters: FErCTGF, plasma CTGF, cortical and medullary
CTGF gene expression (derived from qRT-PCR data of
microdissected kidney, see below), and GFR. In addition
to functional analysis of tubular reabsorption, histological
analysis was performed. We observed no obvious glomerular
damage in diabetic animals, but significant tubular atrophy
was observed (Figures 1(c) and 1(d)), which correlated with
ueCTGF (𝑟 = 0.62, 𝑃 = 0.005, Figure 1(e)). This is consistent
with tubular function as a major determinant of elevated
ueCTGF.
3.2. In Diabetic Mice, a Large Part of uCTGF Is Intrarenally
Derived. To investigate the relative contribution of plasma-
derived eCTGF to ueCTGF, we compared the fractional
excretion (FE) of recombinant and endogenous CTGF.
Assuming that rCTGF and eCTGF are handled similarly by
the kidney, comparison of FErCTGF and FEeCTGF allowed us
to estimate the contribution of plasma-derived eCTGF to
ueCTGF, the ratio FErCTGF/FEeCTGF representing the fraction
of urinary eCTGF derived from plasma. This revealed that
only 37 (29–55)% of urinary eCTGF could be accounted
for by plasma-derived eCTGF, implying that most urinary
CTGFs in diabetes must be derived from an intrarenal source
and excreted into the tubular lumen (Figure 2). Due to
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Figure 1: Urinary CTGF and tubular dysfunction in diabetic mice. (a)The fractional excretion of recombinant CTGF (FErCTGF), a measure of
tubular reabsorption failure, is increased in diabetes, ∗∗𝑃 = 0.004 (Mann-Whitney𝑈 test). (b) Urinary endogenous CTGF excretion (eCTGF)
correlates tightly with FErCTGF, 𝑟 = 0.95, 𝑃 < 0.0001. (c) Tubular atrophy is not present in control mice but clearly visible in diabetic mice
(white arrows). (d) Semiquantitative evaluation shows increased tubular atrophy in diabetic versus control mice, ∗∗∗∗𝑃 < 0.0001 (Mann-
Whitney 𝑈 test). (e) Urinary eCTGF correlates with tubular atrophy, 𝑟 = 0.62, 𝑃 = 0.005.
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Figure 2: In diabetic mice, plasma-derived endogenous CTGF
(eCTGF) accounts for 37% of urinary eCTGF (ueCTGF), while
intrarenally derived CTGF accounts for 63% of ueCTGF (median
with interquartile range).
the extremely low ueCTGF in healthy animals, the relative
contribution of plasma-derived eCTGF to ueCTGF in the
healthy situation could not be established.
3.3. CTGF Production Is Increased in Diabetic Kidney and
Mainly Localized in Glomeruli and Medullary Tubules. To
investigate the localization of intrarenal CTGF production,
we performed CTGF in situ hybridization. This showed that
CTGF expression was hardly detectable in control kidneys
but abundant in diabetic kidneys, where it was mainly
present in glomeruli and medullary tubules (Figure 3(a)). In
agreement, qRT-PCR of microdissected kidney revealed that
both cortical and medullary CTGF mRNA were significantly
increased in diabetic animals compared with controls (2.5-
fold and 2.7-fold, resp., both 𝑃 < 0.01, Figure 3(b)). We did
not observe differences in CTGFmRNA expression in cortex
or medulla between animals infused with rCTGF or with
vehicle, both in diabetic mice and in nondiabetic controls
(data not shown).
3.4. Urinary Excretion of Intrarenally Produced CTGF Cor-
relates with the Degree of Tubular Dysfunction. Intrarenally
derived uCTGF showed a tight linear correlation with
FErCTGF (𝑟 = 0.92, 𝑃 < 0.0001, slope 1.0 on a logarithmic
scale, Figure 4(a)). Cortical CTGF expression also correlated
with intrarenally derived uCTGF (𝑟 = 0.78, 𝑃 = 0.002,
Figure 4(b)), while no such correlation was observed for
medullary CTGF expression (𝑃 = 0.12, Figure 4(c)). In a
multivariate model including cortical and medullary gene
Table 2: General and clinicalcharacteristics of the diabetic patients.
Diabetic patients
𝑁 (% man) 279 (46)
Normoalbuminuria (𝑁 (%)) 142 (61)
Microalbuminuria (𝑁 (%)) 64 (23)
Macroalbuminuria (𝑁 (%)) 73 (26)
Age (years) 52 (41–62)
Duration of diabetes (years) 35 (26–42)
Body mass index (kg/m2) 24 (22–26)
HbA1c (%) 8.4 (7.7–9.3)
Estimated GFR (mLmin−1 1.73m−2) 75 (61–87)
Plasma CTGF (pmol/L) 136 (<127–270)
Urinary CTGF (pmol/g creatinine) 81 (54–118)
Data are median (interquartile range).
expression FErCTGF remained the only independent determi-
nant of intrarenally derived uCTGF (𝛽 = 1.1, 𝑃 < 0.001).
These data suggest that tubular function is also an important
determinant of intrarenally derived CTGF in the urine.
3.5. Increased uCTGF in Type 1 Diabetic Patients Is Indepen-
dently Associated with Tubular Markers. To investigate the
determinants of uCTGF in human diabetes, we studied the
associations of uCTGF with tubular markers and a glomeru-
lar marker in a cohort of patients with diabetes mellitus
type 1. The clinical characteristics of this patients study are
shown in Table 2. IgG4 was used as marker for glomerular
damage [26]. The low-molecular-weight proteins 𝛽2M and
𝛼1M were used as markers for reduced tubular reabsorption
[27, 28]. KIM-1, NGAL, and NAG were used as markers for
proximal tubular damage [29, 30] and H-FABP as a marker
for distal tubular damage [31, 32]. In univariate analysis,
uCTGF correlatedwith each of the damagemarkers (Table 3).
In a multivariate linear regression model containing age,
sex, eGFR, plasma CTGF, duration of diabetes, BMI, and
HbA1c, each of the tubular markers remained independently
associated with uCTGFwhile the glomerular damagemarker
IgG4 lost its significance (Table 3). When IgG4, the proximal
tubular reabsorption, and proximal tubular injury 𝑍-scores
(or the combined proximal tubular 𝑍-score) and H-FABP
were included simultaneously into the model, both proximal
and distal tubular markers, but not IgG4, were independently
related to uCTGF (Table 3). These findings suggest that
also in human diabetes uCTGF is dependent on tubular
status, with elevated uCTGF reflecting both proximal tubular
dysfunction and pathology in the distal tubule. Plasma CTGF
also emerged as an independent determinant of uCTGF.
4. Discussion
Understanding the different determinants of elevated uCTGF
in diabetes is essential for its proper interpretation as
biomarker and pathogenic factor. Previously, we have shown
that in the healthy kidney filtered CTGF is almost completely
reabsorbed in the proximal tubules by megalin-mediated
endocytosis and that impairment of tubular reabsorption
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Figure 3: In diabetic kidneys, CTGFmRNA expression is increased in glomeruli and medullary tubules. (a) In situ hybridization of CTGF in
control and diabetic mice, with little staining in control mice, and clear staining mainly in glomeruli and medullary tubules. (b) Quantitative
RT-PCR of CTGF, showing increased levels in diabetic mice versus control mice, both ∗∗𝑃 < 0.01 (Mann-Whitney 𝑈 test).
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Figure 4: Urinary excretion of intrarenally produced CTGF correlates with the degree of tubular dysfunction. (a) Tight linear correlation
between intrarenally derived uCTGF and FErCTGF (𝑟 = 0.92, 𝑃 < 0.0001, slope = 1.0±0.1) suggests that tubular reabsorption failure is a major
determinant of intrarenally derived uCTGF. (b) Cortical CTGFmRNA levels correlate with the intrarenally derived urinary CTGF (uCTGF),
𝑟 = 0.78, 𝑃 = 0.002. (c) Medullary CTGF expression does not correlate with intrarenally derived uCTGF.
results in increased urinary excretion of CTGF (in close
correlation with that of 𝛽2M) [16]. Here we show that also in
diabetes tubular damage is a major determinant of elevated
uCTGF. Our findings indicate that in addition to reduced
proximal reabsorption of uCTGF increased intrarenal CTGF
production plays a role.
Both in human and in experimental diabetes, uCTGF
was independently associated with decreased tubular reab-
sorption. While in experimental diabetes uCTGF correlated
very tightly with tubular dysfunction, the association in
human diabetes was somewhat less prominent. In addition,
distal tubular damage appeared to play a role. In human
diabetes there was a clear independent association between
uCTGF and distal tubular damage marker H-FABP, sug-
gesting increased CTGF secretion by the distal nephron.
This conforms to the increased distal tubular CTGF mRNA
expression that we observed in diabetic mice, although the
correlation betweenuCTGFandmedullaryCTGFmRNAdid
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Table 3: Association of urinary CTGF with various damage markers in diabetic patients.
Damage marker Model I Model II Model III Model IV
𝜌 P Standard 𝛽 P Standard 𝛽 P Standard 𝛽 P
IgG4 0.155 0.009 0.106 0.063 −0.064 0.264 −0.058 0.302
𝛼1M 0.378 <0.001 0.293 <0.001
𝛽2M 0.335 <0.001 0.226 <0.001
KIM-1 0.226 <0.001 0.176 0.002
NAG 0.166 0.005 0.145 0.012
NGAL 0.235 <0.001 0.187 0.001
H-FABP 0.371 <0.001 0.387 <0.001 0.258 <0.001 0.251 0.001
Proximal tubular reabsorption (PTR) 𝑍-score 0.159 0.014
Proximal tubular injury (PTI) 𝑍-score 0.165 0.004
Combined proximal tubule (PT) 𝑍-score 0.266 <0.001
Plasma CTGF 0.330 <0.001 Variable∗ Variable∗∗ 0.177 0.007 0.180 0.006
Model I: univariate (Spearman’s 𝜌); model II includes age, sex, eGFR, duration of diabetes, BMI, HbA1c, plasma CTGF, and individual urinary marker; model
III includes age, sex, eGFR, duration of diabetes, BMI, HbA1c, plasma CTGF, IgG4, PTR𝑍-score, PTI𝑍-score, andH-FABP; model IV includes age, sex, eGFR,
duration of diabetes, BMI, HbA1c, plasma CTGF, IgG4, PT 𝑍-score, and H-FABP. ∗Standard 𝛽 varies from 0.175 to 0.256 and ∗∗P value from <0.001 to 0.009,
depending on the urinary marker included in the model.
not reach significance. Tubular damagemight thus contribute
to uCTGF in two ways, by (1) decreased proximal reabsorp-
tion of CTGF and (2) increased expression and luminal secre-
tion of CTGF in the distal nephron. Possibly, solute overload
to the distal nephron due to proximal tubular dysfunction
may cause distal tubular injury and induce distal tubular
CTGF expression. Although we are not aware of any clinical,
experimental, or in vitro studies addressing CTGF expres-
sion specifically in medullary tubules in diabetic kidney
disease, increased tubular CTGF protein expression has been
reported before, both in human and in experimental diabetes,
and was postulated to contribute to tubulointerstitial fibrosis
via paracrine effects at the basolateral membrane [4, 33–
35]. However, secretion of CTGF at the apical membrane of
the distal tubular cell into the tubular lumen has not been
described. It would be useful to havematched kidney biopsies
from diabetic patients with known plasma and urine CTGF
levels to explore the associations between increased uCTGF
and pCTGF, tubular dysfunction, and local production of
CTGF. Unfortunately, no matched human kidney biopsies
were available in this study.
Although DN is traditionally viewed as a primarily
glomerular disease, tubulointerstitial injury is also a major
feature of DN with important prognostic significance [36,
37]. Tubular injury was shown to be an early event in the
pathogenesis of DN and tubular proteinuria could identify
patients susceptible to DN even earlier than albuminuria
alone [37–41]. CTGF is upregulated early in DN [42]. In a
nonhuman primate model of diabetes renal CTGF protein
overexpression at 5-year duration of diabetes predicted 10-
year albuminuria values, while at 5-year albuminuria val-
ues did not differ from nondiabetic controls [33]. Elevated
uCTGF reflecting tubular damage might thus be a valuable
prognostic marker in DN and useful for early detection
of patients at risk. As compared to established markers of
tubular damage, CTGF is of particular interest because it
might also enhance tubulointerstitial fibrosis [4, 34, 35].
However, the true clinical value of uCTGF in diabetes still
needs to be established.
In this study, we used a single high dose of STZ to
induce diabetic kidney disease in mice. Since STZ has been
associated with acute tubular injury [43], we cannot exclude
that part of the tubular damage observed in our DN model
might be directly related to STZ toxicity. However, at 10
weeks after infusion of STZ, we expect that the animals
have recovered from the acute toxic effect of STZ. Instead,
they have developed kidney disease in which both chronic
glomerular and tubular damage are present, features that are
also present in human diabetic kidney disease. To deduce
the relative contributions of local production and tubular
dysfunction in uCTGF, a DN model with both glomerular
and tubular features was required. Since both features are
not always present in non-STZ “pure” DN models, which
typically manifest a primarily, if not exclusively, glomerular
and sometimes vascular phenotype, we selected the STZ
model for our studies.
In our mouse model of diabetic kidney disease, we
observed that most uCTGF had a local renal source. In
addition to increased medullary CTGF mRNA expression,
CTGF production was increased in glomeruli, which is in
agreement with previous reports [34, 35, 44–46]. However,
it remains unclear how much intrarenally derived uCTGF
has a glomerular source and how much is secreted at the
apical membrane of the distal tubular cell.The tight indepen-
dent linear association of intrarenally derived uCTGF with
FErCTGF suggests that reduced tubular reabsorption of CTGF
originating from a source upstream the proximal nephron,
that is, the glomerulus, plays an important role.
In human diabetes, but not in experimental diabetes,
plasma CTGF emerged as an independent determinant of
uCTGF. This suggests that in human diabetes the amount
of CTGF filtered from the plasma in the glomeruli also
contributes to uCTGF, in addition to tubular damage. Plasma
CTGF was shown to predict end-stage renal disease and
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mortality inmacroalbuminuric patients [47]. For uCTGF this
has not been investigated yet, but the independent association
with plasma CTGF and tubular damage suggests promising
biomarker value.
In conclusion, urinary CTGF excretion in diabetes is
elevated as a result of both increased local production and
reduced reabsorption due to tubular dysfunction. We submit
that urinary CTGF may be a useful biomarker reflecting
both glomerular and tubulointerstitial hallmarks of diabetic
kidney disease.
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